RESUMEN
Despite advances in the field of transplantation, immunosuppressant medication nonadherence (NA) remains a primary contributor to suboptimal long-term outcomes. Due to the multidimensional and multifactorial causes of medication NA, studies to date have focused on individual differing facets or single point barriers of NA with relative success. However, these successes have not proven to be sustainable, partly due to the intense resources needed for continued viability. This article provides a summary of a 2-day meeting held in April 2017 (Chicago, IL) prior to the American Transplant Congress in which a multidisciplinary group convened to identify the unmet research needs related to medication NA in transplantation. Thought leaders in the field presented the past, present, and future directions of medication NA with the primary outcome of designing, developing, and ranking targeted interventions into a dynamic research agenda to identify which interventions maintained effects over time. Break-out sessions were created based on the five World Health Organization (WHO) dimensions of adherence. Participants were then organized into the newly formed AST Transplant Pharmacy Adherence Consortium (AST TPAC) research group. This meeting report summarizes the content of the symposium, and the development, background, and future directions of the AST TPAC.
Asunto(s)
Rechazo de Injerto/prevención & control , Inmunosupresores/uso terapéutico , Cumplimiento de la Medicación/estadística & datos numéricos , Trasplante de Órganos/efectos adversos , Educación del Paciente como Asunto/normas , Consenso , Rechazo de Injerto/etiología , Humanos , PronósticoRESUMEN
Newer direct-acting antiviral agents have revolutionized the medical management of chronic hepatitis C. In addition to being extremely efficacious, they report very mild adverse drug reactions from experience in clinical trials. However, because they are relatively new on the horizon, postmarketing surveillance studies refining the safety profile are not yet available. We present a case of seizures as a potential side effect of antiviral therapy with sofosbuvir and simeprevir.
Asunto(s)
Antivirales/efectos adversos , Hepatitis C Crónica/tratamiento farmacológico , Convulsiones/inducido químicamente , Simeprevir/efectos adversos , Sofosbuvir/efectos adversos , Humanos , Masculino , Persona de Mediana EdadRESUMEN
BACKGROUND: The cytomegalovirus (CMV) donor-positive/recipient-positive (D+/R+) population is the largest proportion of renal transplant recipients (RTR). Guidelines for prevention of CMV in the intermediate-risk D+/R+ population include prophylaxis with valganciclovir (VGCV) 900 mg/day for 3 months. This study is the first head-to-head analysis, to our knowledge, comparing the efficacy and safety CMV prophylaxis of VGCV 450 vs 900 mg/day for 3 months in D+/R+ RTR. METHODS: A multicenter, retrospective analysis evaluated 478 adult RTR between January 2008 and October 2011. Study participants received VGCV 450 mg/day (Group 1; n=398) or 900 mg/day (Group 2; n=89)×3 months for CMV prophylaxis. All VGCV was adjusted for renal function. All groups included in this study received study-approved induction and maintenance immunosuppression regimens. The primary endpoint was incidence of CMV disease at 12 months. RESULTS: The rates of graft loss, patient survival, T-cell and/or antibody-mediated rejection, hematological adverse events, opportunistic infections, and early VGCV discontinuation were evaluated. Patient demographics were comparable, but had significant differences in ethnicity and donor type between the groups. CONCLUSION: The occurrence of CMV disease at 12 months was similar between the groups (3.5% vs 3.4%; P=1.000). Log-rank test found no statistically significant difference in the time to development of CMV between the 2 groups (P=.939).
Asunto(s)
Profilaxis Antibiótica/métodos , Antivirales/uso terapéutico , Infecciones por Citomegalovirus/prevención & control , Citomegalovirus/aislamiento & purificación , Ganciclovir/análogos & derivados , Trasplante de Riñón/efectos adversos , Adulto , Aloinjertos/virología , Antivirales/administración & dosificación , Antivirales/efectos adversos , Infecciones por Citomegalovirus/sangre , Infecciones por Citomegalovirus/epidemiología , Infecciones por Citomegalovirus/virología , Femenino , Estudios de Seguimiento , Ganciclovir/administración & dosificación , Ganciclovir/efectos adversos , Ganciclovir/uso terapéutico , Rechazo de Injerto/epidemiología , Rechazo de Injerto/inmunología , Humanos , Terapia de Inmunosupresión/métodos , Incidencia , Masculino , Persona de Mediana Edad , Infecciones Oportunistas/epidemiología , Guías de Práctica Clínica como Asunto , Estudios Retrospectivos , Pruebas Serológicas , Receptores de Trasplantes , Resultado del Tratamiento , ValganciclovirRESUMEN
OBJECTIVES: To assess the features and level of health literacy (HL) of available medication adherence apps and to create a searchable website to assist health care providers (HCP) and patients identify quality adherence apps. PRACTICE DESCRIPTION: Medication nonadherence continues to be a significant problem and leads to poor health outcomes and avoidable health care expense. The average adherence rate for chronic medications, regardless of disease state, is approximately 50% leaving significant room for improvement. PRACTICE INNOVATION: Smartphone adherence apps are a novel resource to address medication nonadherence. With widespread smartphone use and the growing number of adherence apps, both HCP and patients should be able to identify quality adherence apps to maximize potential benefits. INTERVENTIONS: Assess the features, functionality and level of HL of available adherence apps and create a searchable website to help both HCP and patients identify quality adherence apps. EVALUATION: Online marketplaces (iTunes, Google Play, Blackberry) were searched in June of 2014 to identify available adherence apps. Online descriptions were recorded and scored based on 28 author-identified features across 4 domains. The 100 highest-scoring apps were user-tested with a standardized regimen to evaluate their functionality and level of HL. RESULTS: 461 adherence apps were identified. 367 unique apps were evaluated after removing "Lite/Trial" versions. The median initial score based on descriptions was 15 (max of 68; range: 3 to 47). Only 77 apps of the top 100 highest-scoring apps completed user-testing and HL evaluations. The median overall user-testing score was 30 (max of 73; range: 16 to 55). CONCLUSION: App design, functionality, and level of HL varies widely among adherence apps. While no app is perfect, several apps scored highly across all domains. The website www.medappfinder.com is a searchable tool that helps HCP and patients identify quality apps in a crowded marketplace.
Asunto(s)
Alfabetización en Salud/estadística & datos numéricos , Cumplimiento de la Medicación/estadística & datos numéricos , Aplicaciones Móviles/normas , Personal de Salud , Humanos , Administración del Tratamiento Farmacológico , Sistemas Recordatorios/instrumentación , Teléfono InteligenteRESUMEN
OBJECTIVE: Conduct a multisite, survey-based study assessing rates of self-reported depressive symptoms among student pharmacists enrolled in the first 3 years (P1-P3) of 4-year Doctor of Pharmacy (PharmD) curricula. METHODS: This study followed a cross-sectional observational design conducted at Washington State University, College of Pharmacy and Pharmaceutical Sciences, and the University of Arkansas for Medical Sciences, College of Pharmacy. Student pharmacists in the first 3 years of pharmacy school (P1-P3) of the PharmD curricula were invited to voluntarily complete the Center for Epidemiologic Studies Depression Scale (CES-D) to collect self-reported measures of depression. The CES-D is a validated 20-item instrument using a 4-point Likert scale. RESULTS: A total of 1795 surveys were evaluated from P1-P3 students at Washington State University, College of Pharmacy and Pharmaceutical Sciences and University of Arkansas for Medical Sciences, College of Pharmacy over a 4-year period (2019-2022). Overall, 1150 (64.1%) surveys indicated the presence of depressive symptoms on CES-D. The highest rate of reported depressive symptoms was recorded in 2021 (71.4%), notably during the coronavirus disease 2019 pandemic, whereas the lowest rate was prepandemic in 2019 (57.8%). The P1 cohort had the highest depression rate in 2020 and 2021, whereas the P2 cohort was highest in 2019 and 2022. The P3 cohort screening positive for depression increased from 52.6% to 69.3% over the 4-year period. CONCLUSION: This multisite, longitudinal study confirms that self-reported depressive symptoms in student pharmacists are significantly higher than what is reported in undergraduate students. Opportunities exist for pharmacy educators and university wellness services to better identify and serve student pharmacists experiencing depression or depressive episodes.
Asunto(s)
Depresión , Estudiantes de Farmacia , Humanos , Estudios Transversales , Depresión/diagnóstico , Depresión/epidemiología , Educación en Farmacia , Estudios Longitudinales , PrevalenciaRESUMEN
OBJECTIVES: To provide an overview of medication adherence, discuss the potential for smartphone medication adherence applications (adherence apps) to improve medication nonadherence, evaluate features of adherence apps across operating systems (OSs), and identify future opportunities and barriers facing adherence apps. PRACTICE DESCRIPTION: Medication nonadherence is a common, complex, and costly problem that contributes to poor treatment outcomes and consumes health care resources. Nonadherence is difficult to measure precisely, and interventions to mitigate it have been largely unsuccessful. PRACTICE INNOVATION: Using smartphone adherence apps represents a novel approach to improving adherence. This readily available technology offers many features that can be designed to help patients and health care providers improve medication-taking behavior. MAIN OUTCOME MEASURES: Currently available apps were identified from the three main smartphone OSs (Apple, Android, and Blackberry). In addition, desirable features for adherence apps were identified and ranked by perceived importance to user desirability using a three-point rating system: 1, modest; 2, moderate; or 3, high. The 10 highest-rated apps were installed and subjected to user testing to assess app attributes using a standard medication regimen. RESULTS 160 adherence apps were identified and ranked. These apps were most prevalent for the Android OS. Adherence apps with advanced functionality were more prevalent on the Apple iPhone OS. Among all apps, MyMedSchedule, MyMeds, and RxmindMe rated the highest because of their basic medication reminder features coupled with their enhanced levels of functionality. CONCLUSION: Despite being untested, medication apps represent a possible strategy that pharmacists can recommend to nonadherent patients and incorporate into their practice.
Asunto(s)
Teléfono Celular , Computadoras de Mano , Personal de Salud , Cumplimiento de la Medicación , HumanosRESUMEN
Antifungal agents are often prescribed in critically ill patients who are receiving many other medications. When using systemic antifungals, clinicians may possess susceptibility data and they are typically aware of the potential toxicity of these agents. However, the myriad of potential drugs that antifungal agents can interact with is daunting and can be confusing. This article reviews the pharmacokinetic properties of antifungal agents and their clinically relevant drug interactions. The antifungal agents differ markedly in their pharmacokinetic properties and in how they interact with other medicines. The amphotericin B formulations interact with other medicines primarily by reducing their renal elimination or producing additive toxicities. The azoles interact with other medicines primarily by inhibiting biotransformation or by affecting drug distribution and elimination. The echinocandins have the lowest propensity to interact with other medicines. The clinical relevance of antifungal-drug interactions varies substantially. While certain interactions are benign and result in little or no untoward clinical outcomes, others can produce significant toxicity or compromise efficacy if not properly managed through monitoring and dosage adjustment. However, certain interactions produce significant toxicity or compromise efficacy to such an extent that they cannot be managed and the particular combination of antifungal and interacting medicine should be avoided.
Asunto(s)
Antifúngicos/farmacocinética , Antifúngicos/uso terapéutico , Micosis/tratamiento farmacológico , Enfermedad Crítica , Interacciones Farmacológicas , HumanosRESUMEN
The coronavirus identified in 2019 (COVID-19) has caused dramatic disruptions in pharmacy experiential education. Administrators and programs have worked to help external preceptors, faculty members, and students cope with the new realities of virtual or remote experiences and new or increased use of telemedicine. Clear and effective lines of communication as well as well-reasoned and resourced alternative plans are necessary to help manage the current issues and prepare for future challenges. Doctor of Pharmacy programs should enhance their focus not just on the physical health and well-being of students, faculty members, and external preceptors, but also on their mental and emotional health. The full scope of the impact of the pandemic on experiential education in pharmacy is still unclear, but this situation should serve as a stimulus for innovation and rethinking the paradigm of how pharmacy programs educate and prepare students for pharmacy practice.
Asunto(s)
Infecciones por Coronavirus/epidemiología , Educación en Farmacia/organización & administración , Neumonía Viral/epidemiología , Aprendizaje Basado en Problemas/organización & administración , Facultades de Farmacia/organización & administración , Adaptación Psicológica , Betacoronavirus , COVID-19 , Comunicación , Educación a Distancia/organización & administración , Docentes de Farmacia/psicología , Humanos , Pandemias , SARS-CoV-2 , Estudiantes de Farmacia/psicología , Comunicación por VideoconferenciaRESUMEN
Objective. To cross reference the core entrustable professional activities (EPAs) to a complete set of educational guidance documents for the Doctor of Pharmacy (PharmD) curriculum to create a map for pharmacy educators.Methods. The Mapping EPAs Task Force consisted of nine members who first worked independently and then together in small working groups to map five assigned educational guidance documents (eg, Center for the Advancement of Pharmacy Education [CAPE] Outcomes, Accreditation Council for Pharmacy Education [ACPE] Standards 1-4, and the Essential Elements for Core Advanced Pharmacy Practice Experiences [APPEs]) to the Core Entrustable Professional Activities for New Pharmacy Graduates. Four working groups completed the mapping process during phases 1 and 2, which was followed by an independent quality assurance review and consensus in phase 3.Results. All 15 core EPA statements were mapped to one or more of the educational documents. One item from the CAPE Outcomes could not be mapped to a core EPA statement. The first five EPA statements mapped directly to the five elements of the Pharmacists' Patient Care Process: collect, assess, plan, implement, and follow-up: monitor and evaluate.Conclusion. This comprehensive EPA map is the first curriculum crosswalk that encompasses a complete set of educational guidance documents including the Essential Elements for Core APPEs for the Doctor of Pharmacy curriculum. If adopted by the Academy, this curriculum crosswalk will provide pharmacy schools with a common interpretation of important educational guidance documents; serve as the foundation for curricular development, revision, and assessment; and ensure student pharmacists are prepared to enter the pharmacy profession.
Asunto(s)
Educación en Farmacia , Servicios Farmacéuticos , Farmacia , Curriculum , Humanos , FarmacéuticosRESUMEN
OBJECTIVE: To evaluate the effects of beta-adrenergic antagonist therapy on cardiovascular and cerebrovascular outcomes in the treatment of hypertension. DATA SOURCES: Literature searches were conducted using MEDLINE (1966-August 2009), International Pharmaceutical Abstracts (1970-August 2009), and Cochrane Database of Systematic Reviews (until third quarter 2009) to locate clinical trials and meta-analyses comparing beta-blocker therapy with placebo or other antihypertensive agents in patients with hypertension. Bibliographies from relevant research and review articles were reviewed for additional references. STUDY SELECTION AND DATA EXTRACTION: All English-language articles identified from the data sources were reviewed. Articles describing original research with cardiovascular or cerebrovascular outcomes and/or death as either primary or secondary endpoints were included. Articles describing the use of beta-blocker therapy for conditions other than hypertension were not included. DATA SYNTHESIS: Five placebo-controlled studies and 10 active-controlled studies were reviewed. In addition, 11 meta-analyses were evaluated. Placebo-controlled trials of beta-blockers in hypertension provide evidence of reduced risk for stroke, cardiovascular events, and heart failure. Only 2 studies comparing beta-blockers with other antihypertensives found significant benefit with beta-blockers. However, the majority of meta-analyses comparing beta-blockers with other antihypertensive agents show increased risk for stroke with beta-blockers, and some data suggest increased risk for cardiovascular events and all-cause mortality. The majority of data results from studies of atenolol, and many studies employed combination antihypertensive therapies, which often included thiazide diuretics. CONCLUSIONS: Overall, data supporting beta-blockers as preferred therapy in hypertension are inadequate. Although most negative cardiovascular and cerebrovascular outcomes of beta-blockers were associated with atenolol therapy, data supporting other beta-blockers in hypertension are lacking.
Asunto(s)
Antagonistas Adrenérgicos beta/farmacología , Antihipertensivos/farmacología , Hipertensión/tratamiento farmacológico , Atenolol/farmacología , Enfermedades Cardiovasculares/prevención & control , Trastornos Cerebrovasculares/prevención & control , Ensayos Clínicos como Asunto , Humanos , Hipertensión/complicacionesRESUMEN
BACKGROUND: The expanding role of pharmacists has influenced admissions committees to consider nonacademic factors other than grade point average (GPA) and test scores and has focused more attention on holistic admissions. METHODS: Database searches were conducted in PubMed, CINAHL, ERIC, and PsychINFO using keywords, "holistic admissions", "holistic review", and "pharmacy admissions" plus "critical thinking skills", "extracurricular", "communication skills", "essay", or "interview". Overall, 64 studies were identified, 17 were excluded, and ultimately, 47 were reviewed. RESULTS: Holistic admissions is not an industry standard in pharmacy but more so in other health professions. For critical thinking skills, the Health Sciences Reasoning Test (HSRT) was not a good predictor of academic performance even though it was effective in ranking admission applicants. The California Critical Thinking Skills Test (CCTST) however, was a significant predictor for clerkship and practice-related courses. It is unclear whether pharmacy admissions committees are utilizing the Pharmacy College Admissions Test (PCAT) reading and writing scores, the interview, or other measures to evaluate communication skills. The Multiple Mini Interview (MMI) is an effective assessment tool for measuring noncognitive attributes; however, the efficacy of unstructured interviews in evaluating noncognitive skills was less clear. IMPLICATIONS: Academic measures alone are not nuanced enough to predict success throughout the entire curriculum. An integration of factors, both academic and nonacademic, would be more relevant to predict success. Critical thinking skills and extracurricular experiences may be more significant for admissions selection and admissions ranking respectively, and more predictive of academic success during didactic and experiential stages of the curriculum respectively.
Asunto(s)
Empleos en Salud/educación , Criterios de Admisión Escolar/tendencias , Prueba de Admisión Académica , Humanos , Universidades/organización & administraciónRESUMEN
Objective. To determine factors associated with advanced pharmacy practice experience (APPE) performance in the pre-pharmacy and Doctor of Pharmacy (PharmD) curriculum and establish whether performance on the multiple mini interview (MMI) independently predicts APPE evaluation scores. Methods. A multi-case MMI has been used in the admissions process since 2008. Students are scored anywhere from 1 to 7 (unsatisfactory to outstanding) on each interview. Traditional factors (GPA, PCAT, etc.) are also used in the admissions determination. Pearson product-moment correlation and ordinary least squares regression were used to explore the relationships between admissions data, pharmacy GPA, and APPE evaluation scores for the graduating classes of 2011-2014. These analyses identified which factors (pharmacy GPA, PCAT, MMI score, age, gender, rurality, resident status, degree, and underrepresented minority status) related to APPE performance. Results. Students (n=432) had a mean APPE score of 4.6; a mean MMI score of 5.5; mean pharmacy GPA, PCAT and age of 3.14, 73.2, 22.6 years, respectively. Pre-pharmacy GPA and pharmacy GPA positively correlated with mean APPE scores. MMI score demonstrated positive correlations with overall APPE score; including subcategories patient care, documentation, drug information/EBM, public health, and communication. MMI scores were positively related to overall APPE scores in the multivariable regression. Variables showing negative associations with APPE scores included a pre-pharmacy GPA of <3.0 (ref= GPA >3.5) and pharmacy school GPA of >3.0 - 3.5 and GPA 2.6 - 3.0 when compared to GPAs >3.5. Conclusion. GPA (pre-pharmacy and pharmacy) and MMI positively correlate with preceptor-rated performances in the APPE year.
Asunto(s)
Prueba de Admisión Académica/estadística & datos numéricos , Educación en Farmacia/estadística & datos numéricos , Evaluación Educacional/estadística & datos numéricos , Servicios Farmacéuticos/estadística & datos numéricos , Criterios de Admisión Escolar/estadística & datos numéricos , Facultades de Farmacia/estadística & datos numéricos , Estudiantes de Farmacia/estadística & datos numéricos , Adulto , Curriculum/estadística & datos numéricos , Femenino , Humanos , Masculino , Persona de Mediana Edad , Farmacia/estadística & datos numéricos , Estudios Retrospectivos , Universidades/estadística & datos numéricos , Adulto JovenRESUMEN
Academic pharmacy spans several generations including traditionalists, baby boomers, Generation X, and Generation Y, commonly referred to as millennials. It has been suggested that leadership styles must change to accommodate these generational differences in academic pharmacy, yet there are no data of which we are aware, that support this assertion. We contend that leadership styles are derived from one's authentic self and are based on core beliefs and values; therefore, leadership styles must not change to accommodate a specific generation or other subset of academic pharmacy. Instead, effective leaders must change tactics (ie, methods or processes) to reach and influence a specific cohort. This article develops and supports the argument that leadership styles should not change to accommodate generational differences in academic pharmacy.
Asunto(s)
Educación en Farmacia/métodos , Educación en Farmacia/organización & administración , Liderazgo , Objetivos , Humanos , Farmacia , Responsabilidad SocialRESUMEN
BACKGROUND: Nonadherence produces considerable health consequences and economic burden to patients and payers. One approach to improve medication nonadherence that has gained interest in recent years is the use of smartphone adherence apps. The development of smartphone adherence apps has increased rapidly since 2012; however, literature evaluating the clinical app and effectiveness of smartphone adherence apps to improve medication adherence is generally lacking. OBJECTIVE: The aims of this study were to (1) provide an updated evaluation and comparison of medication adherence apps in the marketplace by assessing the features, functionality, and health literacy (HL) of the highest-ranking adherence apps and (2) indirectly measure the validity of our rating methodology by determining the relationship between our app evaluations and Web-based consumer ratings. METHODS: Two independent reviewers assessed the features and functionality using a 4-domain rating tool of all adherence apps identified based on developer claims. The same reviewers downloaded and tested the 100 highest-ranking apps including an additional domain for assessment of HL. Pearson product correlations were estimated between the consumer ratings and our domain and total scores. RESULTS: A total of 824 adherence apps were identified; of these, 645 unique apps were evaluated after applying exclusion criteria. The median initial score based on descriptions was 14 (max of 68; range 0-60). As a result, 100 of the highest-scoring unique apps underwent user testing. The median overall user-tested score was 31.5 (max of 73; range 0-60). The majority of the user tested the adherence apps that underwent user testing reported a consumer rating score in their respective online marketplace. The mean consumer rating was 3.93 (SD 0.84). The total user-tested score was positively correlated with consumer ratings (r=.1969, P=.04). CONCLUSIONS: More adherence apps are available in the Web-based marketplace, and the quality of these apps varies considerably. Consumer ratings are positively but weakly correlated with user-testing scores suggesting that our rating tool has some validity but that consumers and clinicians may assess adherence app quality differently.
RESUMEN
Objective. To identify admissions variable prognostics for academic difficulty in the PharmD curriculum to use for admissions determinations and early identification of at-risk students. Methods. Retrospective multivariate analysis of 2008-2012 admission data were linked with academic records to identify students with academic difficulty (ie, those with Ds, Fs, delayed progression). The influence of prepharmacy grade point average (GPA), composite Pharmacy College Admission Test (PCAT) score, multiple-mini interview (MMI) score, age, credit hours, state residence, and prior degree on academic difficulty was estimated using multivariate logistic regression. Results. Students' (n=587) prepharmacy GPA, composite PCAT score, mean MMI score, and age were 3.6, 72.0, 5.5, 22.8 (SD=4.14 years), respectively. Students having a GPA <3.25, PCAT score <60th percentile, or MMI score <4.5, were approximately 12-, 7-, and 3-times more likely, respectively, to experience academic difficulty than those with a GPA ≥ 3.75, PCAT score >90, or MMI score of 5-6. Conclusion. Using GPA, PCAT, and MMI performance can predict academic difficulty and assist in the early identification of academically at-risk PharmD students.